Medication Management

Kisunla (donanemab) is a new IV anti-amyloid beta-directed monoclonal antibody for adults with mild cognitive impairment or mild dementia due to Alzheimer's disease. 

Study examines the risk of MACE in older patients with inflammatory bowel disease taking immunomodulators or biologics versus 5-aminosalicylic acid (5-ASA).

ISMP Canada shares recommendations to enhance safe use of biosimilar insulins, and faster-acting, longer-acting and higher-concentration insulin analogues.

Research suggests benefits in mild-to-moderate depression, but medication interactions limit its role for many patients. Lower-dose formulations may reduce risk.

Study examines the risk of all-cause mortality with approved and off-label pharmacotherapies for irritable bowel syndrome (IBS).

Since most medications are taken daily, doses outside that interval have a lot of error potential.

Are you anxious about what you don’t remember about anxiety therapy? Well have I got a treat for you. 

‘The promise of a drug holiday may actually inspire patients to take their bisphosphonate.’

Treatment resistance is an emerging challenge requiring pharmacists to employ evidence-based strategies.

Get the info you need on this new product, part of our drug news roundup for April.